生物制剂在痛风治疗中的应用进展  

Research progress of biotechnological drugs in treatment of gout

作　　者：高雅[1] 王晓非[2] 

机构地区：[1]中国医科大学 [2]中国医科大学盛京医院风湿免疫科

出　　处：《中华临床医师杂志（电子版）》2014年第21期124-127,共4页Chinese Journal of Clinicians(Electronic Edition)

基　　金：辽宁省科学计划项目(2011225015)

摘　　要：痛风是嘌呤代谢障碍及尿酸排泄减少引起的代谢性疾病,高尿酸血症是痛风的致病基础。近年来,生物制剂进入人们视野。抗白细胞介素-1(IL-1)类、尿酸氧化酶、肿瘤坏死因子拮抗剂及IL-6受体抗体等药物在治疗痛风的研究中逐渐发展起来,且产生不同程度的疗效。现将国内外痛风治疗的生物制剂及尿酸氧化酶资料进行相关总结,为后续研究提供理论基础。Gout is a metabolic disease associated with purine metabolic disorders and the reduction of uric acid excretion, hypemricemia is the key point. Recently, biotechuologieal drags have come into view. IL-1 irdaibitors, uricase, anti-TNF-α and IL-6 inhibitors are becoming the hot spots and have different therapeutic efficacy. The aim of this review is to focus on the various aspects of different biotechnological drugs and uricase in gouty patients and hope to provide information for further study.

关 键 词：痛风 生物制品 尿酸氧化酶 抗白细胞介素-1类 

分 类 号：R589.7[医药卫生—内分泌]